Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chem...

Konference: 2011 53rd ASH Annual Meeting – účast ČR

Téma: 642. CLL - Therapy, excluding Transplantation: First line therapy

Číslo abstraktu: 290

Autoři: MD Christian H. Geisler, PhD; MD Mars MB van 't Veer, PhD; Wim van Putten, MSc; MD Jesper Jurlander, PhD; MD Jan Andrzej Walewski, Ph.D.; MD Geir Tjonnfjord, PhD; MD Maija Itälä-Remes, PhD; MD Eva Kimby, PhD; doc. MUDr. Tomáš Kozák, Ph.D., MBA; MD Aaron Polliack; MD Shulamiet Wittebol; Fokje Spoelstra, PhD; MD Marinus H.J. Van Oers, PhD

Datum přednesení příspěvku: 12. 12. 2011